Stockreport

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025 Company reducing its workforce by approximately 75% $152.8 million in [Read more]